Senior Director, Global Market Development

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Position Overview

Immunome is seeking an accomplished and globally minded Senior Director, Global Market Development to lead the company’s strategic engagement with Key Opinion Leaders (KOLs), scientific societies, and influential clinical stakeholders across the worldwide desmoid tumor community.

This senior leader will play a critical role in shaping the global scientific and clinical environment for varegacestat and future pipeline assets. As the anchor role in Immunome’s emerging Market Development organization, the Senior Director will build a global KOL strategy that spans the United States, Europe, Canada, Latin America, Asia-Pacific, and other priority regions.

The mission of this role is to build trusted, credible, and compliant relationships with global thought leaders, generate meaningful insights that shape Immunome’s strategy, and help establish Immunome as a worldwide leader in desmoid tumor care.

This person will also collaborate closely with regional teams and guide future market development roles as the company expands.

Responsibilities

Global Market Development Strategy

• Build and lead the global market development strategy for varegacestat, with a focus on cultivating a cohesive, worldwide network of KOLs and clinical influencers.
• Map, segment, and prioritize KOLs across U.S., EU5, Canada, Japan, China, LATAM, and other global markets.
• Ensure Immunome maintains a unified global presence while tailoring engagement to regional scientific, cultural, and clinical nuances.
• Partner closely with the International General Manager and regional commercial leaders to harmonize global and in-country KOL strategies.

Worldwide KOL Engagement

• Develop long-term, credible, and compliant relationships with top desmoid tumor experts, sarcoma specialists, surgical oncologists, pathologists, and researchers across key global centers.
• Lead the global strategy for KOL touchpoints including:
• 1:1 scientific engagements
• Global advisory boards
• Regional roundtables and working groups
• Congress-based interactions (ASCO, ESMO, CTOS, SGO, etc.)
• Ensure global KOL insights are continuously captured, synthesized, and circulated across Immunome to inform decision-making.

Insight Generation & Strategic Guidance

• Lead global thought-leader insight generation, delivering actionable recommendations that shape clinical development plans, label strategy and TPP refinement, launch messaging and disease education, evidence generation and HEOR priorities, market access and HTA strategies, and global lifecycle management
• Track and interpret global competitive intelligence and evolving standards of care in desmoid tumors and broader soft-tissue sarcomas.

Global Scientific Advocacy & Launch Preparation

• Develop and execute a global scientific advocacy plan supporting the launch of varegacestat, ensuring aligned messaging and education worldwide.
• Lead global engagement around pivotal clinical data releases, medical meetings, and publication strategies.
• Work in tight partnership with Medical Affairs to ensure scientific exchange is consistent, compliant, and values-driven across markets.

Congress Leadership & External Visibility

• Lead Immunome’s strategy and presence at major global oncology congresses—coordinating KOL interactions, competitive intelligence capture, and scientific communication.
• Drive strategic planning for Immunome-led global advisory boards, desmoid tumor summits, and clinical collaboration forums.
• Strengthen Immunome’s scientific visibility globally through relationship-building with societies, academic groups, and advocacy organizations.